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Background: High dose statin therapy associates with regression of coronary atherosclerosis. The factors influencing the response of coronary 
atheroma to different statin agents is unknown.
Methods: 1039 patients with coronary artery disease underwent serial IVUS evaluation of total atheroma volume (TAV) before and after treatment 
with rosuvastatin 40 mg or atorvastatin 80 mg for 24 months. This analysis explored factors associated with differential responses in changes in TAV.
Results: Rosuvastatin-treated patients demonstrated greater reductions in LDL-C (47% vs 40%, p<0.0001) and apolipoprotein B (31% vs 27%, 
p=0.0019), and greater increases in HDL-C (13% vs 10%, p=0.018), and apolipoprotein A-I (15% vs 10%, p<0.0001). This pattern associated with a 
greater degree of regression of TAV (-6.4 vs -4.4 mm3, p=0.01). Rosuvastatin produced greater reductions in TAV in older patients (-6.0 vs -4.1 mm3, 
p=0.03), females (-7.2 v -3.2 mm3, p=0.03), diabetics (-8.6 vs -0.9 mm3, p=0.006), patients who had not taken a statin in the last 30 days (-7.2 
vs -3.4 mm3, p=0.03) and in patients who had higher systolic blood pressure (-6.8 vs -4.7 mm3, p=0.03), LDL-C (-7.0 vs -4.6 mm3, p=0.03) or 
triglycerides (-5.7 vs -4.3 mm3, p=0.045) at baseline.
Conclusions: Rosuvastatin produces greater regression of coronary atheroma volume than atorvastatin at its maximal dosage. This analysis shows 
that this benefit applies particularly to patients with a higher burden of atherogenic risk factors.
